Best Current Therapeutic Updates Podcasts (2025)

1
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates 23:19

Play Pause

10d ago23:19

23:19

Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer. CME information and select publications here.

1
Small Cell Lung Cancer — Expert Perspectives on Actual Patient Cases 58:18

1M ago58:18

58:18

Dr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for patients with limited-stage and extensive-stage small cell lung cancer. CME information and select publications here.…

1
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates 17:44

1M ago17:44

17:44

Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.

1
Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances 59:02

2M ago59:02

59:02

Dr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies for localized and advanced non-small cell lung cancer without a targetable mutation. CME information and select publications here.…

1
Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates 1:28:41

2M ago1:28:41

1:28:41

Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations. CME information …

1
For Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS Congress 1:27:39

3M ago1:27:39

1:27:39

Dr Anne Chiang, Dr Erin Schenk, and nurse practitioners Ms Elizabeth Krueger and Ms Beth Sandy discuss the role of bispecific antibodies in the management of small cell lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.By Dr. Neil Love

1
EGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 1:57:51

3M ago1:57:51

1:57:51

Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing treatment decision-making for EGFR-mutated NSCLC at the 2025 ASCO annual meeting. CME information and select publications here.By Dr. Neil Love

1
Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances 58:22

4M ago58:22

58:22

Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer. CME information and select publications here.…

1
Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit 50:15

4M ago50:15

50:15

Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches.  CME information and select publications here.By Dr. Neil Love

1
EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit 52:17

5M ago52:17

52:17

Clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer.  CME information and select publications here.By Dr. Neil Love

1
For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress 1:33:02

5M ago1:33:02

1:33:02

Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.…

1
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor 57:28

6M ago57:28

57:28

Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. CME information and select publications here.By Dr. Neil Love

1
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances 1:00:02

8M ago1:00:02

1:00:02

Dr Enriqueta Felip from the Vall d’Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer. CME information and select publications here…

1
Navigating Dating & Relationships During the Holidays 7:22

9M ago7:22

7:22

Tis’ the Season: Navigating the Pressures of Relationships & Holiday Dating This time of the year – in addition to being the holidays – is also known as “cuffing season.” It is a time of the year when single people look to connect in shorter-term relationships to get through the holidays and colder winter months. It unofficially runs from October t…

1
Cases from the Community: Integrating New Research Findings into Current Practice — Lung Cancer 48:03

10M ago48:03

48:03

Dr Edward B Garon shares his perspectives on the evolving therapeutic landscape for patients with lung cancer.By Research To Practice

1
Meet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer 58:47

10M ago58:47

58:47

Dr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer.By Research To Practice

1
The Implications of Recent Datasets for the Current and Future Management of Lung Cancer — A Review of Information from ESMO Congress 2024 and Other Conferences 1:00:12

10M ago1:00:12

1:00:12

Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York discuss the implications of recent data sets for the current and future management of lung cancer.By Research To Practice

1
“Healing Narcissism, Creating A Healthy You & Healthy Relationship Connections” 35:57

10M ago35:57

35:57

“Healing Narcissism, Creating A Healthy You & Healthy Relationship Connections”Our Autumn 🍂 Podcast Series continues with Therapist, Coach &Author, Matthew Phipher.As we continue to focus on intergenerational healing in our practice and psycho, educational outreach work, in the series, we identify what narcissism looks like, how to identify it, how…

1
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Lung Cancer 1:05:42

11M ago1:05:42

1:05:42

Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer.By Research To Practice

1
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from Recent Major Conferences 54:40

11M ago54:40

54:40

Dr Stephen V Liu from Georgetown University Hospital in Washington, DC, reviews recently presented data with and newly approved therapies for localized and advanced lung cancers.By Research To Practice

1
The Implications of Recent Datasets for the Current and Future Management of Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer Review 42:46

11M ago42:46

42:46

Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer.By Research To Practice

1
The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer 1:00:08

12M ago1:00:08

1:00:08

Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations.…

1
The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR 58:14

12M ago58:14

58:14

Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR.…

1
The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations 58:19

12M ago58:19

58:19

Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations.By Research To Practice

1
Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors 59:20

1y ago59:20

59:20

Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors.By Research To Practice

1
Striving for Consensus: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation 2:03:23

1y ago2:03:23

2:03:23

Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates …

1
Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer 1:01:24

1y ago1:01:24

1:01:24

Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting.By Research To Practice

1
Oncology Today with Dr Neil Love: Novel Agents and Strategies in Lung Cancer 1:01:43

1y ago1:01:43

1:01:43

Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Manish Patel from Florida Cancer Specialists & Research Institute in Sarasota, Florida, summarize recently presented advancements, including novel strategies, in the treatment…

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer 1:00:53

1y ago1:00:53

1:00:53

Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 datasets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations.By Research To Practice

1
Oncology Today with Dr Neil Love: An interview with Jonathan W Goldman, MD — Management of Non-Small Cell Lung Cancer with an EGFR Mutation 47:35

1y ago47:35

47:35

Dr Jonathan W Goldman from UCLA Health in Santa Monica, California summarizes recent developments presented at ASCO 2024 for patients with non-small cell lung cancer with an EGFR mutation.By Research To Practice

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer 1:00:48

1+ y ago1:00:48

1:00:48

Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets.By Research To Practice

1
Oncology Today with Dr Neil Love: The Emerging Role of B7-H3-Targeted Antibody-Drug Conjugates 1:14:03

1+ y ago1:14:03

1:14:03

Dr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors.By Research To Practice

1
Oncology Today with Dr Neil Love: Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung Cancer 1:02:58

1+ y ago1:02:58

1:02:58

Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with established and investigational targets in patients with non-small cell lung cancer.By Research To Practice

1
Implications of Recent Data Sets for the Current and Future Management of Lung Cancer 1:30:17

2y ago1:30:17

1:30:17

Dr Luis Paz-Ares from the National Oncology Research Center in Madrid, Spain, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, and Dr David R Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss key presentations from the 2023 ESMO Congress for the management of lung cancer.…

1
Updates in the Treatment of Patients with EGFR Exon 20 Insertion Mutation NSCLC 10:17

2y ago10:17

10:17

This podcast provides an overview of current and emerging data available in the treatment of EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer, including updates from ESMO 2023. Key takeaways:- Review treatment options for EGFR Exon 20 Insertion Mutations in NSCLC - Review updated clinical data from ELCC and ESMO 2023 - Gain an understandi…

1
Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer 1:01:40

2y ago1:01:40

1:01:40

Dr Jamie Chaft and Dr John Heymach discuss the optimal integration of targeted therapy and immunotherapy into the care of patients with localized non-small cell lung cancer.By Research To Practice

1
Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy 2:43:37

2y ago2:43:37

2:43:37

Dr Corey Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands discuss the optimal current management of relapsed NSCLC and provide perspectives on the future of care for patients with this disease.By Research To Practice

1
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting 32:16

2y ago32:16

32:16

Featuring a discussion on key presentations on lung cancer from the 2023 ASCO Annual Meeting, with Dr Matthew Gubens, moderated by Dr Neil Love.By Research To Practice

1
Are Etiquette and Thank You Notes Still Even a Thing and Why It Matters? NPR/KUT Radio. 7:06

2y ago7:06

7:06

Summer is a busy time for weddings, especially in June. And especially the Austin, Texas area – even in this heat! Weddings have a lot of customs and behavioral expectations attached to them – etiquette if you will. And that got Central Texas Neuropsychotherapist, LPC, Bella J. Rockman thinking about good manners and behavior – in a time when it ca…

1
“Are You Acting Your Emotional Age?” 6:40

2+ y ago6:40

6:40

Graduation is a rite of passage for people usually around 18 years old or so. That’s chronological age. But what about our “emotional age” – how we have developed and matured emotionally? Well, that can be a very different story. KUT’s Jennifer Stayton talked recently with Central Texas neuropsychotherapist Bella J. Rockman about the phenomenon of …

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer 1:03:20

2+ y ago1:03:20

1:03:20

Proceedings from our Year in Review webinar on immunotherapy and other nontargeted approaches for lung cancer. Featuring perspectives from Drs Luis Paz-Ares and Heather Wakelee, moderated by Dr Neil Love.By Research To Practice

1
Recent Advances and Future Directions in Lung Cancer — With Dr Ibiayi Dagogo-Jack and Stephen Liu (Proceedings from a Symposium in Partnership with NCOA and SCOS) 59:05

2+ y ago59:05

59:05

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring per…

1
Striving for Consensus on the Management of ALK-Positive Lung Cancer 2:29:53

2+ y ago2:29:53

2:29:53

Featuring a discussion on the management of ALK-positive lung cancer with Dr Ross Camidge, Dr Justin Gainor, Prof Solange Peters and Prof Ben Solomon, moderated by Dr Neil Love.By Research To Practice

1
Oncology Today with Dr Neil Love: Management of HER2-Altered Non-Small Cell Lung Cancer? 1:20:06

2+ y ago1:20:06

1:20:06

Featuring a discussion on targeted therapy for HER2-altered non-small cell lung cancer with Dr Bob Li, moderated by Dr Neil Love.By Research To Practice

1
Oncology Today with Dr Neil Love: Management of Metastatic Non-Small Cell Lung Cancer without an Actionable Mutation 49:37

2+ y ago49:37

49:37

Featuring a discussion on new and emerging data in the management of NSCLC without an actionable mutation, with Dr Edward Garon, moderated by Dr Neil Love.By Research To Practice

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer 1:00:16

2+ y ago1:00:16

1:00:16

Proceedings from our Year in Review webinar on targeted therapy for non-small cell lung cancer. Featuring perspectives from Drs Zofia Piotrowska and Gregory Riely, moderated by Dr Neil Love.By Research To Practice

1
Depression in Patients with Cancer 27:56

4y ago27:56

27:56

Presenter: Philip R. Muskin MD, MA, DLFAPA Professor of Psychiatry Columbia University Irving Medical Center Senior Consultant in Consultation-Liaison Psychiatry New York-Presbyterian Hospital New York, NY Chronic medical illnesses such as cancer are characterized by a notably increased prevalence of depression. Furthermore, several challenges may …

1
Optimal Treatment of Metastatic TNBC 29:30

4y ago29:30

29:30

Presenter: Hope S. Rugo MD Professor of Medicine University of California San Francisco Comprehensive Cancer Center TNBC comprises approximately 15% of newly diagnosed breast cancer cases and is defined by being estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor receptor 2-negative. This breast cancer subt…

1
Using Available Evidence and Guidelines for Managing an Evolving AML Treatment Paradigm 27:20

4y ago27:20

27:20

Presenter: Gail J. Roboz MD Professor of Medicine Director, Clinical and Translational Leukemia Program Weill Medical College of Cornell University New York-Presbyterian Hospital New York, New York, United States This brief program will begin with a review of NCCN Guidelines® Recommendations for the treatment of AML in individuals 60 years of age o…

1
Grief in a Year of Loss 6:41

4+ y ago6:41

6:41

How to process grief in a year filled with loss (and what not to say to those grieving, too)--- Support this podcast: https://podcasters.spotify.com/pod/show/bella-rockman/support